INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAB4. A total of 12 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $13,769,000 | -8.3% | 21,000,000 | -16.0% | 0.02% | -10.5% |
| Q4 2020 | $15,009,000 | -9.6% | 25,000,000 | +5.0% | 0.02% | -17.4% |
| Q3 2020 | $16,598,000 | +192.6% | 23,800,000 | +205.1% | 0.02% | +155.6% |
| Q2 2020 | $5,673,000 | -36.4% | 7,800,000 | -24.3% | 0.01% | -43.8% |
| Q1 2020 | $8,917,000 | -35.1% | 10,300,000 | 0.0% | 0.02% | -20.0% |
| Q4 2019 | $13,731,000 | -5.0% | 10,300,000 | -35.6% | 0.02% | -16.7% |
| Q3 2019 | $14,460,000 | +41.8% | 16,000,000 | +56.0% | 0.02% | +41.2% |
| Q2 2019 | $10,198,000 | – | 10,255,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| PenderFund Capital Management Ltd. | 9,295,000 | $12,549 | 3.76% |
| Context Capital Management, LLC | 23,076 | $22,612 | 1.81% |
| Weiss Asset Management LP | 16,160,000 | $15,847,974 | 0.94% |
| Anson Funds Management LP | 4,000,000 | $3,920,000 | 0.79% |
| SYQUANT CAPITAL SAS | 2,000,000 | $1,961 | 0.77% |
| DG Capital Management, LLC | 1,101,000 | $1,082,834 | 0.59% |
| Skaana Management L.P. | 2,000,000 | $1,957,600 | 0.48% |
| AQR Arbitrage LLC | 6,130,000 | $6,046,019 | 0.27% |
| OAKTREE CAPITAL MANAGEMENT LP | 7,295,000 | $7,195,058 | 0.10% |
| GABELLI & Co INVESTMENT ADVISERS, INC. | 225,000 | $220,658 | 0.04% |